ES2138662T3 - Produccion de fragmentos de anticuerpos. - Google Patents

Produccion de fragmentos de anticuerpos.

Info

Publication number
ES2138662T3
ES2138662T3 ES94917088T ES94917088T ES2138662T3 ES 2138662 T3 ES2138662 T3 ES 2138662T3 ES 94917088 T ES94917088 T ES 94917088T ES 94917088 T ES94917088 T ES 94917088T ES 2138662 T3 ES2138662 T3 ES 2138662T3
Authority
ES
Spain
Prior art keywords
production
antibody fragments
partition
immunoglobin
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917088T
Other languages
English (en)
Inventor
John Landon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Inc
Original Assignee
Therapeutic Antibodies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939311507A external-priority patent/GB9311507D0/en
Priority claimed from GB9402593A external-priority patent/GB9402593D0/en
Application filed by Therapeutic Antibodies Inc filed Critical Therapeutic Antibodies Inc
Application granted granted Critical
Publication of ES2138662T3 publication Critical patent/ES2138662T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pens And Brushes (AREA)
  • Memory System Of A Hierarchy Structure (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN METODO PARA PREPARAR FRAGMENTOS DE INMUNOGLOBINA POLICLONAL (FAB) QUE INCLUYE LA PARTICION DE MOLECULAS DE INMUNOGLOBINA, CARACTERIZADO POR QUE DICHA PARTICION SE LLEVA A CABO EN INMUNOGLOBULINAS EN SANGRE, SERUM O PLASMA EN UN MEDIO CERRADO Y ESTERIL.
ES94917088T 1993-06-03 1994-06-03 Produccion de fragmentos de anticuerpos. Expired - Lifetime ES2138662T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311507A GB9311507D0 (en) 1993-06-03 1993-06-03 Antibody fragments
GB9402593A GB9402593D0 (en) 1994-02-10 1994-02-10 Antibody fragments

Publications (1)

Publication Number Publication Date
ES2138662T3 true ES2138662T3 (es) 2000-01-16

Family

ID=26303001

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94917087T Expired - Lifetime ES2108460T3 (es) 1993-06-03 1994-06-03 Fragmentos de anticuerpos en terapeutica.
ES94917088T Expired - Lifetime ES2138662T3 (es) 1993-06-03 1994-06-03 Produccion de fragmentos de anticuerpos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94917087T Expired - Lifetime ES2108460T3 (es) 1993-06-03 1994-06-03 Fragmentos de anticuerpos en terapeutica.

Country Status (16)

Country Link
US (2) US5733742A (es)
EP (3) EP0916678A3 (es)
JP (1) JP2953782B2 (es)
AT (2) ATE183513T1 (es)
AU (2) AU678483B2 (es)
CA (1) CA2163032C (es)
DE (2) DE69420137T2 (es)
DK (2) DK0703925T3 (es)
ES (2) ES2108460T3 (es)
FI (1) FI955798L (es)
GB (1) GB2294267B (es)
GR (2) GR3025133T3 (es)
NO (1) NO954643D0 (es)
NZ (1) NZ266838A (es)
RU (1) RU2139092C1 (es)
WO (2) WO1994029348A2 (es)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
GB9517538D0 (en) * 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
ATE465257T1 (de) 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6136958A (en) * 1996-09-30 2000-10-24 Genentech, Inc. Antibodies to vertebrate smoothened proteins
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
CA2318029C (en) 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
WO2002009755A2 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
JP5305553B2 (ja) 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
US7317087B2 (en) 2002-03-25 2008-01-08 The Uab Research Foundation Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof
ATE549064T1 (de) 2002-06-14 2012-03-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004048936A2 (en) 2002-11-26 2004-06-10 University Of Utah Research Foundation Microporous materials, methods, and articles for localizing and quantifying analytes
US7597936B2 (en) 2002-11-26 2009-10-06 University Of Utah Research Foundation Method of producing a pigmented composite microporous material
US7335759B2 (en) * 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7141015B2 (en) * 2003-05-09 2006-11-28 Bernard Joseph Ruane Expandable and pivotally adjustable surgical retractor
MXPA06000965A (es) * 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
WO2005069969A2 (en) 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
BRPI0509367A (pt) 2004-03-30 2007-09-11 Glaxo Group Ltd anticorpo, fragmento de ligação de antìgeno, composição farmacêutica, métodos de tratar um paciente humano afligido com uma doença ou distúrbio, de triar um anticorpo, e de detectar hosm em uma amostra biológica, uso de um anticorpo terapêutico ou fragmento de ligação de antìgeno, medicamento, vetor, polunucleotìdeo, célula hospedeira recombinante estavelmente transformada ou transfectada, e, processo para a fabricação de um anticorpo terapêutico
TWI439284B (zh) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
RU2403261C2 (ru) 2005-04-15 2010-11-10 Дженентек, Инк. Варианты бета-цепи hgf
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
JP5757495B2 (ja) 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
EP1998792B1 (en) 2006-03-01 2015-02-18 The University of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CN102391358B (zh) 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
JP2010514839A (ja) 2007-01-03 2010-05-06 バーナム インスティテュート フォー メディカル リサーチ クロット結合化合物に関連する方法および組成物
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
WO2008121437A2 (en) 2007-02-08 2008-10-09 The Burnham Institute For Medical Research Trophinin-binding peptides and uses thereof
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
CN101688194B (zh) 2007-05-23 2013-09-11 Uab研究基金会 去毒的肺炎球菌神经氨酸酶及其用途
SG182183A1 (en) 2007-06-08 2012-07-30 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2010070380A2 (en) 2007-12-03 2010-06-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health Doc1 compositions and methods for treating cancer
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
PT2119726E (pt) 2008-05-14 2015-03-30 Immatics Biotechnologies Gmbh Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
AU2008360658B2 (en) 2008-08-15 2015-02-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S0X9, prostaglandin D2 and retinoic acid for treating pigmentary conditions and melanoma
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
EP2512497A1 (en) 2009-12-18 2012-10-24 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
CA2787070A1 (en) 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
CN103201290B (zh) 2010-06-14 2016-09-28 莱克拉生物医学股份公司 S100a4抗体及其治疗用途
EP2585145B1 (en) 2010-08-19 2014-03-05 West Pharmaceutical Services, Inc. Rigid needle shield
US9051619B2 (en) 2011-03-25 2015-06-09 Florida Agricultural and Mechanical University (FAMU) Methods and compositions for prostate cancer metastasis
EA201301090A1 (ru) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Антидоты антикоагулянтов
PL221015B1 (pl) * 2011-04-11 2016-02-29 Akademia Medyczna Im Piastów Śląskich Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
RU2013155695A (ru) 2011-06-30 2015-08-10 Дженентек, Инк. Препараты антител против с-мет
CA2850178C (en) 2011-09-30 2020-02-25 Sarcotein Diagnostics, Llc Bin1 expression as a marker of cancer
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
US9177997B2 (en) 2011-12-13 2015-11-03 Sony Corporation Memory device
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
CA2875451A1 (en) 2012-06-08 2013-12-12 Kinki University Antibody against transporter and use thereof
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US20140094383A1 (en) 2012-10-02 2014-04-03 Ohio State Innovation Foundation Tethered Lipoplex nanoparticle Biochips And Methods Of Use
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
US10407503B2 (en) 2012-11-30 2019-09-10 The Regents Of The University Of California Fully human antibodies and fragments recognizing human c-Met
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP2942627A1 (en) 2014-05-05 2015-11-11 MicroBPlex, Inc. Media elaborated with newly synthesized antibodies (mensa) from recently proliferated antibody secreting cells (asc) and uses thereof
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HK1246394A1 (zh) 2015-03-02 2018-09-07 Sarcotein Diagnostics Llc 13+/17+bin1表达作为心脏病症的标记
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Innovative peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) 2015-07-06 2021-01-06 Immatics Biotechnologies Gmbh Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
PE20181583A1 (es) 2016-03-01 2018-10-04 Immatics Biotechnologies Gmbh Peptido recombinante derivado de la proteina duoxa2
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
EP3430046A4 (en) 2016-03-16 2019-10-23 Abeome Corporation NEUTRALIZING MONOCLONAL ANTIBODIES TO IL-25 AND USES THEREOF
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
EP3848393A1 (en) 2016-05-18 2021-07-14 Boehringer Ingelheim International GmbH Antibody molecules for cancer treatment
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
CN109952369B (zh) 2016-10-05 2024-03-22 弗罗里达中央大学研究基金会 涉及nk细胞和抗pdl1癌症治疗的方法和组合物
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2018118887A1 (en) 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
GB201701404D0 (en) 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3595705A1 (en) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Method
SG11201906404RA (en) 2017-03-20 2019-08-27 Vaccinex Inc Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
CN110636855B (zh) 2017-03-28 2024-08-09 俄亥俄州创新基金会 人pd1肽疫苗及其用途
EP3385699A1 (en) 2017-04-07 2018-10-10 Universitat Rovira i Virgili Optofluidic device and method for detecting circulating tumour cells
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
CR20210160A (es) 2017-04-10 2021-04-26 Immatics Biotechnologies Gmbh Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508)
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
RU2020106732A (ru) 2017-07-14 2021-08-16 Дзе Фрэнсиз Крик Инститьют Лимитед Анализ аллелей hla в опухолях и его применения
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
MX2019015360A (es) 2017-10-02 2020-02-07 Laboratorios Silanes S A De C V Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.
EP3723770A4 (en) 2017-12-13 2021-11-24 North Carolina State University COMPOSITIONS INCLUDING CHEMOTHERAPEUTIC AGENTS AND CHECKPOINT INHIBITORS AND METHODS OF USE
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
EP3802616A4 (en) 2018-06-04 2022-03-30 University of Maryland, Baltimore PROCEDURES FOR THE PREVENTION OF AN ACUTE KIDNEY LESION
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
CA3104664A1 (en) 2018-06-29 2020-01-02 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
CA3108770A1 (en) 2018-08-08 2020-02-13 Vanderbilt University Systems and methods for simultaneous detection of antigens and antigen specific antibodies
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
EP4588483A3 (en) 2018-10-03 2025-09-24 University of Pittsburgh- Of the Commonwealth System of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020115223A1 (en) 2018-12-05 2020-06-11 Katholieke Universiteit Leuven S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
EP3902607A4 (en) 2018-12-27 2023-04-19 University Of Utah Research Foundation COMPOSITIONS AND METHODS USEFUL IN DETECTING AND TREATMENT OF MULTIPLE SCLEROSIS AND OTHER DEMYELINIZING DISEASES
WO2020206233A1 (en) 2019-04-04 2020-10-08 Vanderbilt University Therapeutic antibodies for treating lung cancer
EP3947445A1 (en) 2019-04-04 2022-02-09 Vanderbilt University Hiv/hcv cross-reactive antibodies and uses thereof
WO2020225549A1 (en) 2019-05-06 2020-11-12 The Francis Crick Institute Limited Method for preventing inflammation
CA3135592A1 (en) 2019-05-20 2020-11-26 Xiaochao Ma Therapeutic agents for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
KR20220044490A (ko) 2019-06-21 2022-04-08 백시넥스 인코포레이티드 세마포린-4d 차단(sema4d) 및 dc1 요법을 사용한 조합 요법
WO2021011747A1 (en) 2019-07-16 2021-01-21 Children’S National Medical Center Method for treatment of muscular dystrophy
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
US12416037B2 (en) 2020-01-24 2025-09-16 Vanderbilt University Methods for identification of ligand-blocking antibodies and for determining antibody potency
CN115443171A (zh) 2020-05-08 2022-12-06 诺沃库勒有限责任公司 向多能干细胞施加交变电场的组合物和方法
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
US20230181743A1 (en) 2020-05-21 2023-06-15 Ohio State Innovation Foundation Functional lipid derivatives and uses thereof
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
EP4433084A1 (en) 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN114132883B (zh) * 2021-11-29 2023-12-22 义乌市奥飞创意设计有限公司 一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备
WO2024013315A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
KR20250134582A (ko) 2022-11-10 2025-09-11 이뮤비아 인코포레이티드 Dr5 및 muc16에 결합하는 세포독성 이중특이성 항체 및 이의 용도
WO2024229369A2 (en) 2023-05-03 2024-11-07 Board Of Regents, The University Of Texas System Antibodies targeting human leukocyte antigen cathepsin g peptide complex
EP4761754A2 (en) 2023-08-18 2026-06-24 Immatics Biotechnologies GmbH Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL186239B (nl) 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4822776A (en) 1981-09-08 1989-04-18 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
AU560087B2 (en) 1981-09-08 1987-03-26 Rockefeller University, The Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
CA1260828A (en) 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
DE3342870A1 (de) * 1983-11-26 1985-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4849352A (en) * 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
ATE114673T1 (de) 1985-08-16 1994-12-15 Univ Rockefeller Modulator der anabolischen aktivität und seine verwendungen.
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4918163A (en) 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
US4731244A (en) 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy
JPH01501476A (ja) 1986-10-09 1989-05-25 ネオルックス　コーポレイション 抗体、抗体断片、ホルモン並びに他の標的剤、およびそれらの配合体を標的とする改良方法
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
DE3823804A1 (de) * 1988-07-14 1990-01-18 Basf Ag Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
JP2638652B2 (ja) * 1988-07-18 1997-08-06 カイロン・コーポレーション カケクチンと反応するモノクロナール抗体
EP0355067A1 (en) 1988-08-19 1990-02-21 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
ATE147634T1 (de) 1988-12-19 1997-02-15 American Cyanamid Co Produkte zur behandlung des endotoxin -schocks bei einem säugetier
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
EP0486526B2 (en) * 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
JPH0747547B2 (ja) * 1989-12-04 1995-05-24 シェリング・コーポレーション 敗血症性ショック治療用医薬組成物
US5110913A (en) * 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
GB9023783D0 (en) 1990-11-01 1990-12-12 Celltech Ltd Pharmaceutical product
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
AU5152293A (en) 1992-10-08 1994-05-09 Kennedy Institute Of Rheumatology, The Treatment of autoimmune and inflammatory disorders
EP0646000A4 (en) 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy

Also Published As

Publication number Publication date
DE69405102T2 (de) 1998-01-15
JPH08511015A (ja) 1996-11-19
ES2108460T3 (es) 1997-12-16
AU678483B2 (en) 1997-05-29
GR3025133T3 (en) 1998-02-27
GB9524064D0 (en) 1996-02-21
CA2163032A1 (en) 1994-12-22
FI955798A7 (fi) 1996-02-01
US5733742A (en) 1998-03-31
DE69420137D1 (de) 1999-09-23
GB2294267A (en) 1996-04-24
DK0703925T3 (da) 1999-12-06
FI955798L (fi) 1996-02-01
US6193969B1 (en) 2001-02-27
EP0701571B1 (en) 1997-08-20
NZ266838A (en) 1997-02-24
DK0701571T3 (da) 1997-09-15
FI955798A0 (fi) 1995-12-01
NO954643L (no) 1995-11-17
GB2294267B (en) 1996-11-20
AU6852594A (en) 1995-01-03
ATE157100T1 (de) 1997-09-15
DE69405102D1 (en) 1997-09-25
JP2953782B2 (ja) 1999-09-27
WO1994029347A1 (en) 1994-12-22
DE69420137T2 (de) 1999-12-23
AU6852494A (en) 1995-01-03
CA2163032C (en) 2001-02-06
EP0701571A1 (en) 1996-03-20
EP0703925B1 (en) 1999-08-18
NO954643D0 (no) 1995-11-17
RU2139092C1 (ru) 1999-10-10
WO1994029348A2 (en) 1994-12-22
ATE183513T1 (de) 1999-09-15
EP0916678A3 (en) 1999-05-26
EP0703925A1 (en) 1996-04-03
EP0916678A2 (en) 1999-05-19
GR3031415T3 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
NO970292L (no) Bestemmelse av et spesifikt immunoglobulin ved anvendelse av multiple antigener
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ATE177754T1 (de) Fragmente von prion proteinen.
ATE208820T1 (de) Humanisierte antikoerper
AU691995B2 (en) Interference-suppressing reagent specific to certain classes of antibodies
ATE160575T1 (de) Für toxin b von clostridium difficile spezifische monoklonale antikörper
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
GB2294267B (en) Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
EP0143209A3 (en) Method for the immunological determination of proteins in body fluids using monovalent antibody fragments
NO20010747L (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
ES551494A0 (es) Procedimiento de obtencion de un anticuerpo monoclonal reactivos con antigenos de esporozoitos o merozoitos de eimeria spp.
IL123736A0 (en) Tryptase polyclonal antibody and purification method for use in human immunoassay
DK407987A (da) Apolipoprotein b-specifikke monoklonale antistoffer og hybridomer, som producerer disse antistoffer
NO163920C (no) Fremgangsmaate for bestemmelse av pivka-ii i fysiologiske proever.
ES2072423T3 (es) Anticuerpo monoclonal e inmunoensayo para el factor beta xiia de coagulacion de la sangre.
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ES2115022T3 (es) Inmunoensayo de isotiazolonas.
ES2056919T3 (es) Anticuerpo monoclonal especifico para la fosfolipasa a2 pancreatica humana.
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ES2061973T3 (es) Anticuerpos monoclonales que reconocen la region n-terminal de polipeptido natriuretico auricular, su preparacion y uso.
DK329789D0 (da) Monoklonalt antistof
ES2082040T3 (es) Anticuerpos monoclonales que reconocen a la fosfolipasa a2 de membrana e inmunoensayos de fosfolipasa a2 de membrana.
ES2126608T3 (es) Procedimiento para la determinacion de antigenos o anticuerpos en presencia de un inmunocomplejo.
ES2125011T3 (es) Procedimiento inmunologico de la antitrombina iii activada por un glicosaminoglicano, anticuerpos monoclonales correspondientes y su procedimiento de obtencion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 703925

Country of ref document: ES